Media coverage about American Renal Associates (NYSE:ARA) has been trending somewhat positive on Thursday, Accern Sentiment reports. Accern identifies negative and positive press coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. American Renal Associates earned a news impact score of 0.12 on Accern’s scale. Accern also gave news articles about the company an impact score of 49.7138410283764 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
Here are some of the media stories that may have effected Accern’s rankings:
- Recent Analysis Shows Paycom Software, American Renal Associates, Knowles … (globenewswire.com)
- Leerink Swann Analysts Increase Earnings Estimates for American Renal Associates (ARA) (americanbankingnews.com)
- American Renal Associates (ARA) to Post Q2 2018 Earnings of $0.15 Per Share, SunTrust Banks Forecasts (americanbankingnews.com)
- American Renal Associates Holdings’ (ARA) CEO Joseph Carlucci on Q1 2018 Results – Earnings Call Transcript (seekingalpha.com)
- Analysts Expect American Renal Associates (ARA) Will Post Quarterly Sales of $199.35 Million (americanbankingnews.com)
Shares of American Renal Associates traded down $0.57, reaching $15.26, during trading hours on Thursday, Marketbeat Ratings reports. 8,028 shares of the stock traded hands, compared to its average volume of 177,732. The company has a market cap of $489.81 million, a P/E ratio of 25.02, a P/E/G ratio of 0.74 and a beta of 2.10. American Renal Associates has a one year low of $15.18 and a one year high of $15.68. The company has a quick ratio of 1.10, a current ratio of 1.15 and a debt-to-equity ratio of 4.63.
American Renal Associates (NYSE:ARA) last released its quarterly earnings results on Tuesday, May 8th. The company reported $0.11 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.09 by $0.02. The business had revenue of $194.67 million during the quarter, compared to the consensus estimate of $189.10 million. American Renal Associates had a return on equity of 16.88% and a net margin of 0.60%. The business’s quarterly revenue was up 10.0% compared to the same quarter last year. During the same period in the previous year, the company posted $0.07 EPS. research analysts anticipate that American Renal Associates will post 0.7 EPS for the current fiscal year.
A number of equities analysts have weighed in on ARA shares. Leerink Swann reissued a “market perform” rating and issued a $22.00 target price (down previously from $27.00) on shares of American Renal Associates in a research report on Wednesday, April 25th. Zacks Investment Research downgraded American Renal Associates from a “hold” rating to a “sell” rating in a research note on Tuesday, January 23rd.
About American Renal Associates
American Renal Associates Holdings, Inc operates as a dialysis services provider in the United States. It operates dialysis clinics focusing on joint venture partnerships with physicians. The company offers kidney dialysis services to patients suffering from chronic kidney failure or end stage renal disease.
Receive News & Ratings for American Renal Associates Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for American Renal Associates and related companies with MarketBeat.com's FREE daily email newsletter.